Taylor & Francis

Hello and welcome to today’s latest episode of OC Talks Podcast by Oncology Central. My name is Jade Parker, Senior Editor of Oncology Central, and I am joined by Volkmar Mϋller from University Medical Center Hamburg-Eppendorf in Germany. Today we are going to discuss HER2-positive breast cancer including the unmet needs of the disease, and our hopes for the future.

In this Tech Blast episode, BioTechniques' Digital Editor, Annie Coulson, discusses single domain antibodies with ProSci’s Andy Lee, Lead Scientist of the Single Domain Antibody Program, and David Eling, Director of Business Development. Andy and David describe what single domain antibodies (sdAbs) are, including their unique characteristics, such as their small size. They then go on to explore the applications of sdAbs, from increasing resolution in imaging studies, to developing antidotes for snake venom.

Listen to this episode to get an overview of sdAbs, how they could be incorporated into your research and their link to llamas.

Contents:

Introductions: 00:00–01:25

What are single domain antibodies? 01:25–3:05

Applications of single domain antibodies: 03:05–05:05

Unique characteristics of sdAbs: 05:05–07:55

sdAbs for SARS-CoV-2: 07:55–08:35

sdAbs for therapeutics and diagnostics: 08:35–11:25

Unique applications, including biosensors and animal feed: 11:25–12:50

Working with researchers to develop sdAbs: 12:50–13:25

The future of sdAbs: 13:25–15:50

Closing remarks: 15:50–16:20

In this Tech Blast episode, our Digital Editor Annie Coulson talks with Carlo Messina, Senior Director for Oncology in Global Development and Medical Affairs at Roche (Basel, Switzerland), about the use of comprehensive genomic profiling (CGP) in cancer research.

CGP can obtain more information about a tumor from a smaller biospecimen compared with other genomic profiling techniques and gives oncologists more tools for treating patients. Carlo talks about the applications of CGP, including detecting genomic aberrations in the bloodstream, and the future of this technique.

In this episode, supported by BrandTech, returning guest Rob Vries, CEO of HUB organoids (Utrecht, The Netherlands), fills us in on the advancement of 3D cell cultures and organoids over the last 2 years, starting off by documenting how the pandemic impacted their development and uptake.

We also discuss how the recent FDA Modernization Act, removing the requirement for drug candidates to be tested on animals, has impacted the drive for improved models, the key techniques available to analyze them and what still needs to change for 3D cell cultures to fully replace animal models in the lab.

Listen today to find out which resources can help you begin to work with 3D cell cultures, their most exciting recent applications and how issues of reproducibility are currently being addressed in the field.

Contents:Intro: 00:00-00:50How COVID-19 impacted the uptake and development of 3D cell cultures: 00:50-02:05Key developments in 3D cell culture technology in the last 2 years: 02:05-03:00Intestinal organoids and the investigation of irritable bowel syndrome: 03:00-5:50Evaluating assembloids: 05:50-08:35Complexity vs clinical relevance: 08:35-10:45The impact of 3D cell cultures in precision medicine in cancer: 10:45-12:40The impact of the FDA’s Modernization Act on 3D cell culture uptake: 12:40-14:45What needs to improve in organoid technologies to fully replace animal models? 14:45-16:10Changing inbuilt reliance on animal models: 16:10-18:30Key techniques to analyze organoids: 18:30-19:50Developments in imaging technology that have improved the analysis of organoids: 19:50-21:15Current challenges in 3D cell culture implementation and reproducibility: 21:15-24:15Improving access to 3D cell cultures: 24:15-25:55Resources to help people implement organoids into their work: 25:55-27:15Searching for the holy grail in 3D cell cultures: 27:15-28:00

In this episode of Editor’s Picks, presented by guest-host Grace Tyrrell, learn about how the need for vaccine refrigeration could be on the way out, a new chemical approach that may aid in the fight against antibiotic resistance and the use of AI algorithms as a potential cure for drug-resistant epilepsy.

Welcome to OC talks, a podcast series exploring the latest advancements in oncology. I’m your host, Jade Parker, Oncology Central’s Senior Editor. In this episode, supported by Sengenics, we will be exploring the importance of autoantibodies in the development of cancer as well as how they can be used in the early detection of tumors.

Joining me for this episode is Field Application Scientist Joseph Miseirvitch from Sengenics, a precision medicine company working to improve patient outcomes for physiologically relevant, data-guided decision making.

BZ PPD Spotlight Podcast: an interview with Cyrille Bonhomme by Taylor & Francis Group

In this episode of Talking Techniques, supported by Bio-Rad, we discuss a key component of many gene therapies: recombinant adeno-associated viruses (rAAVs) and their production. These viruses act as efficient, accurate delivery vesicles for the gene therapy’s plasmid.

Speaking to Associate Director of Biopharma Product Marketing at Bio-Rad Laboratories, Mark White, we take a look the different expression systems used for their production and compare their advantages, before looking at some of the challenges involved in the production rAAVs, such as host cell contamination.

Discover the tools that can help minimize host cell contamination and differentiate between nuclease resistant and nuclease reactive contaminant DNA and find out about some of the most exciting developments in rAAV technologies.  

Contents:The role of rAAVs in gene therapies: 00:40-02:15

The production of rAAVs and gene therapies: 02:15-03:30

Why are HEK cells so popular for cell therapy production? 03:30-05:45

HEK vs SF9 Insect cell expression systems: 05:45-06:45

Challenges in cell therapy expression systems: 06:45-08:05

Host DNA contamination: 08:05-10:30

The risks of host DNA contamination: 10:30-12:45

Key techniques to minimize host DNA contamination: 12:45-14:40

The advantages of ddPCR in gene therapy production: 14:40-17:50

Distinguishing between nuclease resistant and nuclease reactive host cell DNA: 17:50-19:10

The most exciting developments in rAAV technology: 19:10-20:20

What is one thing you would ask for to improve rAAV and gene therapy development 20:20-26:38

In this episode of Editor’s Picks, hosted by our Assistant Editor Aisha Al-Janabi, learn about recent concerns over the validity of a pivotal Alzheimer’s disease study, how researchers answered a question about the heart dating back to the 1600s and a laser-based diamond sensing technology that improves magnetoencephalography precision.

In many regions of the world, HPV and its association with cervical cancer is a well-known but rarely considered issue, after the rollout of the HPV vaccine in the late 2000s. However, while this rollout significantly impacted cervical cancer rates where it was implemented, it was not universal and in many areas of the world HPV induced cervical cancer remains a critical issue.

Cervical cancer is the leading cause of death for people with a cervix living in poverty in low-resource regions and on the continent of Africa, it is estimated that in 2020 as many people with a cervix died of cervical cancer as COVID-19.

In this episode of Talking techniques, supported by Oxford Nanopore, Senior Investigator Michael Dean and Post-baccalaureate Fellow Nicole Rossi, from the NIH’s National Cancer Institute (MD, USA), discuss their research into the relationship between HPV and cervical cancer. Expounding on the points mentioned above, they reveal the tremendous insights into cancer and immunology still to be gained, document the key tools used in their studies and explain how their work can be translated into more effective immunotherapies and treatments for cervical cancer.

ContentsIntroduction: 00:00-01:40How big an issue does HPV present to the world? 01:40-03:30HPV’s association with cancer: 03:30-05:15Why does HPV target DNA repair mechanisms? 05:15-06:00Key goals of research into HPV: 06:00-07:15Challenges of HPV research: 07:15- 08:20Solutions available to deal with these challenges: 08:20-09:30The most exciting discoveries in HPV using long-read sequencing: 09:30-11:00HPV16- the most oncogenic variant: 11:00-11:40Translating research into clinical results for HPV: 11:40-12:45How effective is the current HPV vaccine? 12:45-13:30What would you ask for to improve research into HPV and cancer? 13:30-14:30How big an issue is vaccine rejection? 14:30-15:40Final thoughts: 15:40-17:00